Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clarus' Jatenzo Suffers From Off-Label Concerns At US Advisory Committee

Executive Summary

Oral testosterone candidate loses close vote as many panelists worry that convenience could spur misuse; REMS could offer reassurance.


Related Content

Spring Awakening: NDA Submissions To Watch For
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
Oral Testosterones Might Use REMS, CV Post-Market Study To Win Approval
Jatenzo v. Tlando: Similar Issues Did Not Lead To Similar Votes
Recent And Upcoming FDA Advisory Committee Meetings
Lipocine's Tlando Falls Short At US FDA Advisory Cmte Over Blood Pressure Concerns
Lipocine Testosterone Therapy Faces Safety, Stopping Criteria Concerns At US FDA Advisory Cmte
Oral Testosterone Therapy Jatenzo Faces CV, Sampling Tube Issues At Advisory Cmte
Clarus’ Oral Testosterone’s Perceived Advantage Becomes Downfall At FDA Panel


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts